These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 7874268)
1. Changes of antigen expression on human hepatoma cell lines caused by sodium butyrate, a differentiation inducer. Saito H; Tada S; Ebinuma H; Tsunematsu S; Kagawa T; Kumagai N; Inagaki Y; Watanabe T; Tsuchimoto K; Morizane T J Gastroenterol; 1994 Dec; 29(6):733-9. PubMed ID: 7874268 [TBL] [Abstract][Full Text] [Related]
2. Reduction of LAK-sensitivity and changes in antigen expression on hepatoma cells by sodium butyrate. Tada S; Saito H; Ebinuma H; Atsukawa K; Masuda T; Tsunematsu S; Morizane T; Ishii H Cancer Biochem Biophys; 1996 Apr; 15(3):177-86. PubMed ID: 8937741 [TBL] [Abstract][Full Text] [Related]
3. Differentiating effect of sodium butyrate on human hepatoma cell lines PLC/PRF/5, HCC-M and HCC-T. Saito H; Morizane T; Watanabe T; Kagawa T; Miyaguchi S; Kumagai N; Tsuchiya M Int J Cancer; 1991 May; 48(2):291-6. PubMed ID: 1708367 [TBL] [Abstract][Full Text] [Related]
4. Loss of butyrate-induced apoptosis in human hepatoma cell lines HCC-M and HCC-T having substantial Bcl-2 expression. Saito H; Ebinuma H; Takahashi M; Kaneko F; Wakabayashi K; Nakamura M; Ishii H Hepatology; 1998 May; 27(5):1233-40. PubMed ID: 9581676 [TBL] [Abstract][Full Text] [Related]
5. Effect of dexamethasone, dimethylsulfoxide and sodium butyrate on a human hepatoma cell line PLC/PRF/5. Saito H; Kagawa T; Tada S; Tsunematsu S; Guevara FM; Watanabe T; Morizane T; Tsuchiya M Cancer Biochem Biophys; 1992 Nov; 13(2):75-84. PubMed ID: 1285320 [TBL] [Abstract][Full Text] [Related]
7. Suppression of growth of hepatocellular carcinoma by sodium butyrate in vitro and in vivo. Yamamoto H; Fujimoto J; Okamoto E; Furuyama J; Tamaoki T; Hashimoto-Tamaoki T Int J Cancer; 1998 Jun; 76(6):897-902. PubMed ID: 9626359 [TBL] [Abstract][Full Text] [Related]
8. Multiplicity of newly established monoclonal antibodies against hepatocellular carcinomas. Ohzu K; Hasegawa K; Yamauchi K; Obata H J Gastroenterol Hepatol; 1990; 5(6):601-7. PubMed ID: 1966596 [TBL] [Abstract][Full Text] [Related]
9. Recombinant human interleukin 1 alpha is cytotoxic for and increases surface expression of HLA-A,B,C antigens of a human hepatoma cell line, PLC/PRF/5. Yoshioka K; Fuji A; Tahara H; Arao M; Kakumu S Immunobiology; 1989 Feb; 178(4-5):380-9. PubMed ID: 2541069 [TBL] [Abstract][Full Text] [Related]
10. Butyrate enhances major histocompatibility complex class I, HLA-DR and ICAM-1 antigen expression on differentiated human intestinal epithelial cells. Siavoshian S; Blottière HM; Bentouimou N; Cherbut C; Galmiche JP Eur J Clin Invest; 1996 Sep; 26(9):803-10. PubMed ID: 8889444 [TBL] [Abstract][Full Text] [Related]
11. Human hepatoma cells expressing MHC antigens display accessory cell function: dependence on LFA-1/ICAM-1 interaction. Paroli M; Carloni G; Franco A; De Petrillo G; Alfani E; Perrone A; Barnaba V Immunology; 1994 Jun; 82(2):215-21. PubMed ID: 7927492 [TBL] [Abstract][Full Text] [Related]
12. A novel human tumor necrosis factor alfa mutein, F4614, inhibits in vitro and in vivo growth of murine and human hepatoma: implication for immunotherapy of human hepatocellular carcinoma. Atarashi Y; Yasumura S; Nambu S; Yoshio Y; Murakami J; Takahara T; Higuchi K; Watanabe A; Miyata K; Kato M Hepatology; 1998 Jul; 28(1):57-67. PubMed ID: 9657097 [TBL] [Abstract][Full Text] [Related]
13. [Expression of human hepatoma associated antigen in relation to the cell cycle]. Zhu XY Zhonghua Zhong Liu Za Zhi; 1991 Sep; 13(5):322-4. PubMed ID: 1664314 [TBL] [Abstract][Full Text] [Related]
14. Expression of the SART1 tumor-rejection antigen in hepatocellular carcinomas. Yutani S; Shichijo S; Inoue Y; Kawagoe N; Okuda K; Kurohiji T; Tanaka M; Sata M; Itoh K Oncol Rep; 2001; 8(2):369-72. PubMed ID: 11182058 [TBL] [Abstract][Full Text] [Related]
15. Gangliosides and sialoglycoproteins carrying a rare blood group antigen determinant, Cad, associated with human cancers as detected by specific monoclonal antibodies. Hiraiwa N; Tsuyuoka K; Li YT; Tanaka M; Seno T; Okubo Y; Fukuda Y; Imura H; Kannagi R Cancer Res; 1990 Sep; 50(17):5497-503. PubMed ID: 2167157 [TBL] [Abstract][Full Text] [Related]
16. Sodium butyrate enhances STAT 1 expression in PLC/PRF/5 hepatoma cells and augments their responsiveness to interferon-alpha. Hung WC; Chuang LY Br J Cancer; 1999 May; 80(5-6):705-10. PubMed ID: 10360647 [TBL] [Abstract][Full Text] [Related]
17. Role of beta1 integrins in adhesion and invasion of hepatocellular carcinoma cells. Masumoto A; Arao S; Otsuki M Hepatology; 1999 Jan; 29(1):68-74. PubMed ID: 9862852 [TBL] [Abstract][Full Text] [Related]
18. Reciprocal regulation of alpha-fetoprotein and albumin gene expression by butyrate in human hepatoma cells. Tsutsumi T; Ido A; Nakao K; Hamasaki K; Kato Y; Ohtsuru A; Nakata K; Tamaoki T; Nagataki S Gastroenterology; 1994 Aug; 107(2):499-504. PubMed ID: 7518784 [TBL] [Abstract][Full Text] [Related]
19. Potential therapeutic value of dendritic cells loaded with NY‑ESO‑1 protein for the immunotherapy of advanced hepatocellular carcinoma. Chen Y; Huang A; Gao M; Yan Y; Zhang W Int J Mol Med; 2013 Dec; 32(6):1366-72. PubMed ID: 24085111 [TBL] [Abstract][Full Text] [Related]
20. Vascular adhesion protein-1 and ICAM-1 support the adhesion of tumor-infiltrating lymphocytes to tumor endothelium in human hepatocellular carcinoma. Yoong KF; McNab G; Hübscher SG; Adams DH J Immunol; 1998 Apr; 160(8):3978-88. PubMed ID: 9558106 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]